Sugi Predict

Sugi Predict / Compounds / SCHEMBL155503

SCHEMBL155503

SCHEMBL155503

Fc1ccc(Br)cc1Cc1cc2ccccc2s1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SLC5A2 P31639 7/20 0.53
▸ SLC5A1 P13866 3/20 0.53
▸ CHRM1 P11229 1/20 0.53
▸ ADRA1A P35348 1/20 0.53
▸ SLC6A3 Q01959 1/20 0.53
▸ CYP2A6 P11509 3/20 0.46
▸ ADRB2 P07550 1/20 0.46
▸ ASIC3 Q9UHC3 1/20 0.46
▸ LOXL2 Q9Y4K0 1/20 0.46
▸ AGXT P21549 1/20 0.43
▸ ADRA1D P25100 2/20 0.43
▸ IDH1 O75874 1/20 0.39
▸ CTRC Q99895 1/20 0.37
▸ NR1D1 P20393 1/20 0.35
▸ NR1H3 Q13133 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzothiophene SCHEMBL5974867 0.91 SLC5A2 (0.47) SLC5A2SLC5A1CHRM1ADRA1ASLC6A3
SCHEMBL155484 0.85 CYP2A6 (0.43) SLC5A2SLC5A1CHRM1ADRA1ASLC6A3
SCHEMBL154422 0.84 SLC5A2 (0.41) SLC5A2SLC5A1CHRM1ADRA1ASLC6A3
SCHEMBL152611 0.84 SLC5A2 (0.41) SLC5A2SLC5A1CHRM1ADRA1ASLC6A3
SCHEMBL19188793 0.82 SLC5A2 (0.53) SLC5A2SLC5A1CHRM1ADRA1ASLC6A3
SCHEMBL28528398 0.82 SLC5A2 (0.53) SLC5A2SLC5A1CHRM1ADRA1ASLC6A3
SCHEMBL14949124 0.82 SLC5A2 (0.53) SLC5A2SLC5A1CHRM1ADRA1ASLC6A3
SCHEMBL158148 0.82 SLC5A2 (0.53) SLC5A2SLC5A1CHRM1ADRA1ASLC6A3
SCHEMBL154549 0.82 CYP2A6 (0.50) SLC5A2SLC5A1CHRM1ADRA1ASLC6A3
SCHEMBL12425724 0.81 CYP2A6 (0.49) SLC5A2SLC5A1CHRM1ADRA1ASLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121270508-A Igliflozin Synthesis method of intermediate 上海柏狮生物科技有限公司 2026-01-06 — — CN disclosed
WO-2025088634-A1 A PROCESS FOR THE PREPARATION OF GLIFLOZIN AGLYCONES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2025-05-01 — — WO disclosed
US-20250042930-A1 METHOD FOR PREPARING ARYL CARBON GLYCOSIDE COMPOUND INCLUDING GLIFLOZIN DRUG SICHUAN UNIVERSITY (CN) 2025-02-06 — — US disclosed
CN-119019476-A Process for producing C-arylalkoxyglycoside derivative and other compounds 株式会社德山 2024-11-26 — — CN disclosed
CN-118546061-A Method for producing acid chloride derivative and method for producing ketone derivative 株式会社德山 2024-08-27 — — CN disclosed
US-12018007-B2 Method for manufacturing diarylmethane compound TOKUYAMA CORPORATION (JP) 2024-06-25 — — US disclosed
US-12018007-B2 Method for manufacturing diarylmethane compound TOKUYAMA CORPORATION (JP) 2024-06-25 — — US disclosed
WO-2023213035-A1 METHOD FOR PREPARING ARYL CARBON GLYCOSIDE COMPOUND INCLUDING GLIFLOZIN DRUG 四川大学 2023-11-09 — — WO disclosed
CN-116730998-A Process for preparing aryl carbon glycoside compound 四川大学华西医院 2023-09-12 — — CN disclosed
EP-3805211-A1 METHOD FOR MANUFACTURING DIARYLMETHANE COMPOUND Tokuyama Corporation (JP) 2021-04-14 — — EP disclosed
US-8202984-B2 Glucopyranoside compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-06-19 — — US disclosed
US-8198464-B2 Method for producing C-glycoside derivative and intermediate for synthesis thereof ASTELLAS PHARMA INC. (JP) 2012-06-12 — — US disclosed
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-08 — — US disclosed
US-7943788-B2 Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-17 — — US disclosed
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-05 — — US disclosed
US-20100094025-A1 METHOD FOR PRODUCING C-GLYCOSIDE DERIVATIVE AND INTERMEDIATE FOR SYNTHESIS THEREOF ASTELLAS PHARMA INC. (JP) 2010-04-15 — — US disclosed
CN-101568537-A Method for producing C-glycoside derivative and synthetic intermediate thereof ASTELLAS PHARMA INC (JP) 2009-10-28 — — CN disclosed
EP-2105442-A1 METHOD FOR PRODUCING C-GLYCOSIDE DERIVATIVE AND SYNTHETIC INTERMEDIATE THEREOF Astellas Pharma Inc. (JP) 2009-09-30 — — EP disclosed
CN-1829729-A Novel compounds TANABE SEIYAKU CO (JP) 2006-09-06 — — CN disclosed
US-20050233988-A1 Novel compounds TANABE SEIYAKU CO., LTD. (JP) 2005-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 SLC5A2 5/4885SLC5A1 13/4885CHRM1 3468/4885
US-20050233988-A1 Novel compounds CYP1B1, CYP4B1, CYP2B6 SLC5A2 472/4885SLC5A1 303/4885CHRM1 2212/4885
US-12018007-B2 Method for manufacturing diarylmethane compound GLP1R, IAPP, ARRB1 SLC5A2 96/4885SLC5A1 110/4885CHRM1 257/4885
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 SLC5A2 5/4885SLC5A1 13/4885CHRM1 3468/4885
US-20250042930-A1 METHOD FOR PREPARING ARYL CARBON GLYCOSIDE COMPOUND INCLUDING GLIFLOZIN DRUG UGGT1, GCG, SLC5A2 SLC5A2 3/4885SLC5A1 6/4885CHRM1 4735/4885
US-20100094025-A1 METHOD FOR PRODUCING C-GLYCOSIDE DERIVATIVE AND INTERMEDIATE FOR SYNTHESIS THEREOF IRS1, IAPP, IDE SLC5A2 48/4885SLC5A1 77/4885CHRM1 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.